Vumedi disclosed a $104 million Series B investment from Oak HC/FT on November 10 alongside an expansion of AI tools that help doctors find and compare specialists’ clinical guidance. The physician-education company said it had already used the capital for hiring, research and product development.
An earlier securities filing recorded about $80 million in equity sales, with the first sale dated May 14, 2025. Vumedi’s latest announcement does not explain how that offering relates to the $104 million Series B.
Doctors can ask a treatment question and get a synthesis of specialists’ views, with links to the relevant point in a video or podcast. Vumedi says its searchable library contains more than 100,000 physician-led videos and nearly 5,000 podcast episodes.
Vumedi reports that more than 150,000 verified clinicians have used its AI tools since their launch less than a year ago. Oak says AI users watch 122% more video than nonusers.
Vumedi also works with drug and device brands seeking to reach clinicians. Its website lists more than 100 pharmaceutical brand partners and more than 75 medical-device brand partners. Oak describes the appeal as putting specialists’ perspectives in front of doctors as they consider new treatments.